KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xylem (XYL) EBT (2016 - 2025)

Xylem has reported EBT over the past 16 years, most recently at $368.0 million for Q4 2025.

  • Quarterly results put EBT at $368.0 million for Q4 2025, down 1.87% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (up 8.65% YoY), and the annual figure for FY2025 was $1.2 billion, up 8.65%.
  • EBT for Q4 2025 was $368.0 million at Xylem, up from $297.0 million in the prior quarter.
  • Over the last five years, EBT for XYL hit a ceiling of $375.0 million in Q4 2024 and a floor of $17.0 million in Q3 2022.
  • Median EBT over the past 5 years was $187.0 million (2022), compared with a mean of $192.7 million.
  • Biggest five-year swings in EBT: crashed 87.22% in 2022 and later skyrocketed 988.24% in 2023.
  • Xylem's EBT stood at $126.0 million in 2021, then soared by 50.0% to $189.0 million in 2022, then increased by 11.11% to $210.0 million in 2023, then surged by 78.57% to $375.0 million in 2024, then dropped by 1.87% to $368.0 million in 2025.
  • The last three reported values for EBT were $368.0 million (Q4 2025), $297.0 million (Q3 2025), and $299.0 million (Q2 2025) per Business Quant data.